The non-opioid pain patch market size has grown strongly in recent years. It will grow from $3.34 billion in 2023 to $3.53 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth observed in the historical period can be ascribed to several factors, including a notable increase in chronic pain cases, a preference among patients for non-invasive treatment modalities, advancements in formulations and ingredients, a rise in sports-related injuries, and heightened concerns regarding opioid addiction.
The non-opioid pain patch market size is expected to see steady growth in the next few years. It will grow to $4.25 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The anticipated growth in the forecast period can be attributed to several key factors, including a rise in research and development investments, an increase in healthcare expenditure, a supportive regulatory environment, growing consumer awareness and education, and the expanding geriatric population. Noteworthy trends expected in the forecast period encompass the adoption of wireless and smart patch technologies, the integration of natural ingredients, collaboration with wearable technology, the development of biodegradable and eco-friendly patches, and a notable focus on achieving long-lasting effects.
The anticipated growth in the non-opioid pain patch market is expected to be driven by the increasing prevalence of chronic pain. Chronic pain, characterized by prolonged and often severe discomfort, is a prevalent condition associated with various medical issues. Non-opioid pain patches, designed to alleviate mild to moderate pain, find applications in treating diverse pain types such as headaches, muscle aches, arthritis, and backaches. Notably, in May 2021, the Centers for Disease Control and Prevention (CDC) reported that the prevalence of chronic pain among adults in the United States ranged from 20.5% to 21.8% between 2019 and 2021, with high-impact chronic pain affecting 6.9% to 7.8% of adults during the same period. In 2021, an estimated 51.6 million American adults (20.9%) reported experiencing chronic pain, while 17.1 million (6.9%) reported high-impact chronic pain. This escalating prevalence of chronic pain is a significant driver for the non-opioid pain patch market.
The growth of the non-opioid pain patch market is expected to be fueled by increased research and development (R&D) activities. R&D activities involve investigative work aimed at improving existing products or procedures and developing new solutions. With growing concerns about opioid dependence and side effects, the development of non-opioid pain management options, particularly in patch form, has become a dynamic area of research. For instance, in January 2023, the National Center for Science and Engineering Statistics (NCSES) reported that R&D spending in the United States reached $717.0 billion in 2020 and was estimated to be $791.9 billion in 2021. This substantial investment in R&D activities is contributing to the advancement of non-opioid pain patches, driving their market growth.
Product innovation is emerging as a prominent trend gaining traction in the non-opioid pain patch market, with major companies actively developing innovative solutions to enhance their market positions. An illustrative example is The Mentholatum Company Inc., a UK-based healthcare products manufacturer, which introduced the Deep Relief Actiflex Patch in June 2022. This drug-free pain patch features a cooling hydrogel containing water, offering fast cooling and soothing relief as the water evaporates on the skin. Specifically designed to treat aches and pains in muscles or joints, this innovative patch adds diversity to the non-opioid pain patch market.
Major companies in this market are focusing on the development of advanced products, including biocompatible surgical patches. These medical devices are utilized during surgical procedures to repair or reinforce injured tissues. In March 2021, Duke University, a renowned US-based private research university, introduced a non-opioid painkiller delivery system directly to wounds. This polymer patch delivers medication inhibiting the enzyme COX-2 (cyclooxygenase-2), known for causing pain and inflammation, providing sustained relief for days before naturally dissolving.
In October 2021, Pacira BioSciences, Inc., a US-based provider of non-opioid pain management and regenerative health solutions, made a strategic acquisition by purchasing Flexion Therapeutics, Inc., although the exact amount was undisclosed. This acquisition signifies a significant step forward in Pacira's strategy to establish a robust portfolio of innovative, non-opioid medicines, enhancing patient care along the neurological pain pathway. It also adds a complementary commercial asset in ZILRETTA, designed for the treatment of osteoarthritis knee pain.
Major companies operating in the non-opioid pain patch market report are Hisamitsu Pharmaceutical Co. Inc., Pfizer Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Medtronic PLC, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aurobindo Pharma Limited, Purdue Pharma L.P., Kyowa Kirin Co. Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Apotex Inc., Endo Pharmaceuticals PLC, Lupin Limited, Amneal Pharmaceuticals LLC, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Private Limited, Mallinckrodt Pharmaceuticals LLC, IBSA Institut Biochimque SA, Teikoku Seiyaku Co.Ltd., Acorda Therapeutics Inc., Sorrento Therapeutics Inc., Veridian Healthcare LLC, Clarion Brands LLC, Averitas Pharma Inc.
North America was the largest region in the non-opioid pain patch market in 2023. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-opioid pain patch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of non-opioid pain patches include lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and others. Lidocaine patches, for instance, are transdermal patches with analgesic properties. These patches are composed of a synthetic amide-type anesthetic, lidocaine, formulated in a 5 percent aqueous base solution. They serve the purpose of aiding in the treatment of itching and pain associated with certain skin disorders. Lidocaine patches are distributed through various channels, including hospital pharmacies, retail pharmacies, and other outlets. These patches find applications in treating various conditions, including musculoskeletal pain and neuropathic pain.
The non-opioid pain patch research report is one of a series of new reports that provides non-opioid pain patch market statistics, including the non-opioid pain patch industry's global market size, regional shares, competitors with non-opioid pain patch market share, detailed non-opioid pain patch market segments, market trends and opportunities, and any further data you may need to thrive in the non-opioid pain patch industry. This non-opioid pain patch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The non-opioid pain patch market consists of sales of aspirin, ibuprofen, and acetaminophen patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The non-opioid pain patch market size is expected to see steady growth in the next few years. It will grow to $4.25 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The anticipated growth in the forecast period can be attributed to several key factors, including a rise in research and development investments, an increase in healthcare expenditure, a supportive regulatory environment, growing consumer awareness and education, and the expanding geriatric population. Noteworthy trends expected in the forecast period encompass the adoption of wireless and smart patch technologies, the integration of natural ingredients, collaboration with wearable technology, the development of biodegradable and eco-friendly patches, and a notable focus on achieving long-lasting effects.
The anticipated growth in the non-opioid pain patch market is expected to be driven by the increasing prevalence of chronic pain. Chronic pain, characterized by prolonged and often severe discomfort, is a prevalent condition associated with various medical issues. Non-opioid pain patches, designed to alleviate mild to moderate pain, find applications in treating diverse pain types such as headaches, muscle aches, arthritis, and backaches. Notably, in May 2021, the Centers for Disease Control and Prevention (CDC) reported that the prevalence of chronic pain among adults in the United States ranged from 20.5% to 21.8% between 2019 and 2021, with high-impact chronic pain affecting 6.9% to 7.8% of adults during the same period. In 2021, an estimated 51.6 million American adults (20.9%) reported experiencing chronic pain, while 17.1 million (6.9%) reported high-impact chronic pain. This escalating prevalence of chronic pain is a significant driver for the non-opioid pain patch market.
The growth of the non-opioid pain patch market is expected to be fueled by increased research and development (R&D) activities. R&D activities involve investigative work aimed at improving existing products or procedures and developing new solutions. With growing concerns about opioid dependence and side effects, the development of non-opioid pain management options, particularly in patch form, has become a dynamic area of research. For instance, in January 2023, the National Center for Science and Engineering Statistics (NCSES) reported that R&D spending in the United States reached $717.0 billion in 2020 and was estimated to be $791.9 billion in 2021. This substantial investment in R&D activities is contributing to the advancement of non-opioid pain patches, driving their market growth.
Product innovation is emerging as a prominent trend gaining traction in the non-opioid pain patch market, with major companies actively developing innovative solutions to enhance their market positions. An illustrative example is The Mentholatum Company Inc., a UK-based healthcare products manufacturer, which introduced the Deep Relief Actiflex Patch in June 2022. This drug-free pain patch features a cooling hydrogel containing water, offering fast cooling and soothing relief as the water evaporates on the skin. Specifically designed to treat aches and pains in muscles or joints, this innovative patch adds diversity to the non-opioid pain patch market.
Major companies in this market are focusing on the development of advanced products, including biocompatible surgical patches. These medical devices are utilized during surgical procedures to repair or reinforce injured tissues. In March 2021, Duke University, a renowned US-based private research university, introduced a non-opioid painkiller delivery system directly to wounds. This polymer patch delivers medication inhibiting the enzyme COX-2 (cyclooxygenase-2), known for causing pain and inflammation, providing sustained relief for days before naturally dissolving.
In October 2021, Pacira BioSciences, Inc., a US-based provider of non-opioid pain management and regenerative health solutions, made a strategic acquisition by purchasing Flexion Therapeutics, Inc., although the exact amount was undisclosed. This acquisition signifies a significant step forward in Pacira's strategy to establish a robust portfolio of innovative, non-opioid medicines, enhancing patient care along the neurological pain pathway. It also adds a complementary commercial asset in ZILRETTA, designed for the treatment of osteoarthritis knee pain.
Major companies operating in the non-opioid pain patch market report are Hisamitsu Pharmaceutical Co. Inc., Pfizer Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Medtronic PLC, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aurobindo Pharma Limited, Purdue Pharma L.P., Kyowa Kirin Co. Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Apotex Inc., Endo Pharmaceuticals PLC, Lupin Limited, Amneal Pharmaceuticals LLC, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Private Limited, Mallinckrodt Pharmaceuticals LLC, IBSA Institut Biochimque SA, Teikoku Seiyaku Co.Ltd., Acorda Therapeutics Inc., Sorrento Therapeutics Inc., Veridian Healthcare LLC, Clarion Brands LLC, Averitas Pharma Inc.
North America was the largest region in the non-opioid pain patch market in 2023. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-opioid pain patch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of non-opioid pain patches include lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and others. Lidocaine patches, for instance, are transdermal patches with analgesic properties. These patches are composed of a synthetic amide-type anesthetic, lidocaine, formulated in a 5 percent aqueous base solution. They serve the purpose of aiding in the treatment of itching and pain associated with certain skin disorders. Lidocaine patches are distributed through various channels, including hospital pharmacies, retail pharmacies, and other outlets. These patches find applications in treating various conditions, including musculoskeletal pain and neuropathic pain.
The non-opioid pain patch research report is one of a series of new reports that provides non-opioid pain patch market statistics, including the non-opioid pain patch industry's global market size, regional shares, competitors with non-opioid pain patch market share, detailed non-opioid pain patch market segments, market trends and opportunities, and any further data you may need to thrive in the non-opioid pain patch industry. This non-opioid pain patch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The non-opioid pain patch market consists of sales of aspirin, ibuprofen, and acetaminophen patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Non-Opioid Pain Patch Market Characteristics3. Non-Opioid Pain Patch Market Trends and Strategies32. Global Non-Opioid Pain Patch Market Competitive Benchmarking33. Global Non-Opioid Pain Patch Market Competitive Dashboard34. Key Mergers and Acquisitions in the Non-Opioid Pain Patch Market
4. Non-Opioid Pain Patch Market - Macro Economic Scenario
5. Global Non-Opioid Pain Patch Market Size and Growth
6. Non-Opioid Pain Patch Market Segmentation
7. Non-Opioid Pain Patch Market Regional and Country Analysis
8. Asia-Pacific Non-Opioid Pain Patch Market
9. China Non-Opioid Pain Patch Market
10. India Non-Opioid Pain Patch Market
11. Japan Non-Opioid Pain Patch Market
12. Australia Non-Opioid Pain Patch Market
13. Indonesia Non-Opioid Pain Patch Market
14. South Korea Non-Opioid Pain Patch Market
15. Western Europe Non-Opioid Pain Patch Market
16. UK Non-Opioid Pain Patch Market
17. Germany Non-Opioid Pain Patch Market
18. France Non-Opioid Pain Patch Market
19. Italy Non-Opioid Pain Patch Market
20. Spain Non-Opioid Pain Patch Market
21. Eastern Europe Non-Opioid Pain Patch Market
22. Russia Non-Opioid Pain Patch Market
23. North America Non-Opioid Pain Patch Market
24. USA Non-Opioid Pain Patch Market
25. Canada Non-Opioid Pain Patch Market
26. South America Non-Opioid Pain Patch Market
27. Brazil Non-Opioid Pain Patch Market
28. Middle East Non-Opioid Pain Patch Market
29. Africa Non-Opioid Pain Patch Market
30. Non-Opioid Pain Patch Market Competitive Landscape and Company Profiles
31. Non-Opioid Pain Patch Market Other Major and Innovative Companies
35. Non-Opioid Pain Patch Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Non-Opioid Pain Patch Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on non-opioid pain patch market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for non-opioid pain patch? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Patch: Lidocaine Patches; Diclofenac Patches; Capsaicin Patches; Ketoprofen Patches; Other Patches
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
3) By Indication: Musculoskeletal Pain; Neuropathic Pain
Key Companies Mentioned: Hisamitsu Pharmaceutical Co. Inc.; Pfizer Inc.; Novartis AG; Sanofi S.A.; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Hisamitsu Pharmaceutical Co. Inc.
- Pfizer Inc.
- Novartis AG
- Sanofi S.A.
- GlaxoSmithKline plc
- Medtronic plc
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Aurobindo Pharma Limited
- Purdue Pharma L.P.
- Kyowa Kirin Co. Ltd.
- Boehringer Ingelheim Pharmaceuticals Inc.
- Dr. Reddy's Laboratories Ltd.
- Apotex Inc.
- Endo Pharmaceuticals plc
- Lupin Limited
- Amneal Pharmaceuticals LLC
- Daiichi Sankyo Company Limited
- Glenmark Pharmaceuticals Private Limited
- Mallinckrodt Pharmaceuticals LLC
- IBSA Institut Biochimque SA
- Teikoku Seiyaku Co.Ltd.
- Acorda Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Veridian Healthcare LLC
- Clarion Brands LLC
- Averitas Pharma Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 3.53 Billion |
| Forecasted Market Value ( USD | $ 4.25 Billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
